PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2010; 5(7): e11800.
Published online 2010 July 26. doi:  10.1371/journal.pone.0011800
PMCID: PMC2909910

Role of NAD(P)H Oxidase in Superoxide Generation and Endothelial Dysfunction in Goto-Kakizaki (GK) Rats as a Model of Nonobese NIDDM

Ian Lanza, Editor

Abstract

Background

Cardiovascular disease is the leading cause of mortality in diabetics, and it has a complex etiology that operates on several levels. Endothelial dysfunction and increased generation of reactive oxygen species are believed to be an underlying cause of vascular dysfunction and coronary artery disease in diabetes. This impairment is likely the result of decreased bioavailability of nitric oxide (NO) within the vasculature. However, it is unclear whether hyperglycemia per se stimulates NADPH oxidase-derived superoxide generation in vascular tissue.

Methods and Results

This study focused on whether NADPH oxidase-derived superoxide is elevated in vasculature tissue evoking endothelial/smooth muscle dysfunction in the hyperglycemic (169±4 mg%) Goto-Kakizaki (GK) rat. By dihydroethidine fluorescence staining, we determined that aorta superoxide levels were significantly elevated in 9 month-old GK compared with age matched Wistar (GK; 195±6%, Wistar; 100±3.5%). Consistent with these findings, 10−6 mol/L acetylcholine-induced relaxation of the carotid artery was significantly reduced in GK rats compared with age matched Wistar (GK; 41±7%, Wistar; 100±5%) and measurements in the aorta showed a similar trend (p = .08). In contrast, relaxation to the NO donor SNAP was unaltered in GK compared to Wistar. Endothelial dysfunction was reversed by lowering of superoxide with apocynin, a specific Nox inhibitor.

Conclusions

The major findings from this study are that chronic hyperglycemia induces significant vascular dysfunction in both the aorta and small arteries. Hyperglycemic induced increases in NAD(P)H oxidase activity that did not come from an increase in the expression of the NAD(P)H oxidase subunits, but more likely as a result of chronic activation via intracellular signaling pathways.

Introduction

Of the 24 million diabetic Americans, the vast majority suffer from noninsulin dependent diabetes mellitus or type 2 diabetes, while another 57 million Americans are pre-diabetic. Originally thought to be a metabolic problem, widespread systemic complications are now recognized. Cardiovascular disease is the leading cause of mortality in NIDDM has a complex etiology that operates on several levels to include both atherogenic and myocardial components [1], [2]. The vascular complications include intermittent claudication, atherosclerosis, hypertension, retinopathy, nephropathy, and congestive heart failure. The vascular problems of NIDDM individuals are believed to be traceable to alterations in endothelial function.

Diabetes results in significant impairment of endothelium-dependent vasodilatation in response to acetylcholine or increases in flow. This impairment is likely the result of decreased effectiveness of NO mediated functions within the vasculature. It is unclear if this impairment is the result of decreased NO synthesis or bioavailability as a result of an altered vascular phenotype. NO signaling not only regulates vascular tone, but also inhibits of components of the atherogenic process including platelet aggregation, monocyte adhesion, and vascular smooth muscle migration [3], [4], [5]. Endothelial dysfunction and increased generation of reactive oxygen species are believed to be an underlying cause of vascular dysfunction and coronary artery disease in diabetes. Increased NAD(P)H levels have been observed in the spontaneous diabetic BB rat also a model of type 1 diabetes [6]. We have reported in the Zucker fa/fa, a model of type 2 diabetes, an increase in superoxide generation was observed [7]. All of these models have both components of hyperlipidemia, hypercholesterolemia, and hyperglycemia, and it is unclear if hyperglycemia alone may stimulate NADPH oxidase-derived superoxide generation in vascular tissue.

Increased generation of reactive oxygen species is believed to be an underlying cause of vascular dysfunction and coronary artery disease in diabetes. Recent studies have shown that components of NADPH oxidase are up-regulated in type 1 diabetes in the vasculature [8]. However, it is unclear whether hyperglycemia per se stimulates NADPH oxidase-derived superoxide generation in vascular tissue. The GK rats are a nonobese model of NIDDM that have elevated fasting glucose, impaired response to glucose, and increased HbA1c levels at an early age [9], [10], [11]. Compared to other diabetic animal models, including the Zucker fa/fa and Leprdb mouse, the GK rats are not severely hyperlipidemic or hypercholesterolemic and present as a model of hyperglycemia [7], [12]. Therefore, the objective of this study was to elucidate whether endothelial or smooth muscle dysfunction was evident in the hyperglycemic GK rats and the potential role NADPH oxidase function may have.

Materials and Methods

Animal Model

Male euglycemic Wistar and diabetic Goto-Kakizaki rats were used throughout this study (with the exception of Figure 1A) [13]. The GK rats are a nonobese model of NIDDM that have elevated fasting glucose, impaired response to glucose, and increased HbA1c levels at an early age [9], [10], [11]. Experimental protocols using animals had approval from the New York Medical College Institutional Animal Care and Use Committee (A3362-01). Animals were maintained in accordance with institutional polices and the Public Health Service (NIH[ratio]PHS) Policy on Humane Care and Use of Laboratory Animals (revised 8/2002).

Figure 1
GK rats are hyperglycemic.

Glucose Tolerance Test (GTT)

Glucose was tested following an overnight fast and started between 0930 and 1030 the following morning. The animals were injected with Nembutal (40 mg/kg, i.p.), and then at least 15 minutes allotted to achieve a suitable plane of anesthesia. Sterile glucose (1.0 g/kg i.p.) was injected into the abdominal cavity being careful to avoid the g–i tract. Tail vein blood (50 µl) was sampled at selected intervals (pre-injection, 15, 30, 60, 120 min). HbA1c was determined using the A1CNow kits (Bayer Healthcare, Tarrytown NY). Blood glucose was determined using an Accu-Chek monitor (Roche Diagnostics, Indianapolis, IN) calibrated using known standards. At the end of the protocol, the animals were given an addition injection of Nembutal (75 mg/kg, i.p.) prior to tissue harvest.

Vessel isolation and functional studies

The aorta of each animal were carefully exposed and isolated from the surrounding tissues. The vessels were cleaned from the adventitia using an operating microscope and microsurgery instruments. Endothelial function was assessed as previously described [14], [15]. In brief, aortic segments of each animal were cut into ring segments 1.5 mm in length and mounted on 40 µm stainless steel wires in the myographs chambers (Danish Myo Technology A/S, Inc., Denmark) for measurement of isometric tension. The vessels were superfused with Krebs buffer solution (118 mmol/L NaCl, 4.7 mmol/L KCl, 1.5 mmol/L CaCl2, 25 mmol/L NaHCO3, 1.1 mmol/L MgSO4, 1.2 mmol/L KH2PO4, and 5.6 mmol/L glucose; at 37°C; gassed with 95% air and 5% CO2). After an equilibration period of 1 hour during which a optimal passive tension was applied to the rings (as determined from the vascular length-tension relationship), relaxations of pre-contracted (by 10−6 mol/L phenylephrine) vessels to acetylcholine (ACh; from 10−8 to 10−6 mol/L) and the NO donor S-nitrosopenicillamine (SNAP, from 10−9 to 10−5 mol/L) were obtained.

Microvascular dilation

NO-mediated microvascular responses were compared by assessing acetylcholine-induced dilation in isolated, pressurized first-order skeletal muscle arterioles, as we previously reported [16].

Dihydroethidine fluorescence

Production of O2.− was determined in segments of the aortas that were used for functional studies. Hydroethidine, an oxidative fluorescent dye, was used to localize superoxide production in situ as we previously reported [17]. In brief, vessels were incubated with hydroethidine (3×10−6 mol/L; at 37°C for 60 min). The arteries were then washed three times, embedded in OCT medium and cryosectioned. Fluorescent images were captured at ×10 magnification and analyzed using the Zeiss Axiovision imaging software. Ten to fifteen entire fields per vessel were analyzed with one image per field. The mean fluorescence intensities of ethidium–stained nuclei in the endothelium and medial layer were calculated for each vessel. Thereafter, these intensity values for each animal in the group were averaged. Unstained aortas and vessels pre-incubated with PEG-SOD were used for background correction and negative control, respectively.

Superoxide Activity

In brief, aortas were homogenized in ice-cold buffer (20 mM HEPES-pH 7.4, 0.1 mmol/L EDTA, 1 mM glutathione, 10−5 mol/L BH4, 1× proteinase inhibitor. Protein concentration was determined by the Bradford method. NADPH oxidase activity, using 5 µM lucigenin, was determined as we have previously described [18]. NOX-dependent activity was determined by the addition of (3×10−4 mol/L apocynin, 5×10−5 mol/L gp91ss-tat, or 10−6 mol/L diphenyleneiodonium (DPI).

Western Blot Analysis

Tissues were stored at −80°C until used. Aorta samples were homogenized in ice-cold buffer (20 mmol/L HEPES pH7.5, 50 mmol/L NaCl, 1% SDS, 1× protease inhibitor (Sigma-Aldrich, P-8340). Protein concentration was determined by the Bradford method (BioRad reagent). Samples were mixed with Lamelli buffer, heated to 95°C for 5 min, and loaded onto a SDS-PAGE and electrophoresis was performed at room temperature. The gels were blotted onto Hybond-P (Amersham Biosciences, Piscataway NJ) by a semi-dry transfer protocol. Western analysis was performed as described previously [19]. Antibodies used included mouse monoclonal anti-Nox-1, anti-Nox-2, anti-p67phox, and smooth muscle alpha-actin (Transduction Laboratory, San Jose, CA, USA), goat polyclonal anti-Nox-4 and anti-p47phox (Santa Cruz Biotech, Santa Cruz, CA). Antibody dilutions were 1[ratio]500 for all Nox subunits and 1[ratio]2000 for alpha-actin. Antibody binding was visualized using the Amersham ECL Plus kit. Band density was quantified using AlphaEaseFC software (AlphaInnotech, San Leando CA).

RNA Analysis

Total RNA from was isolated using a FASTRNA ProGreen Kit (Q-Biogene, Irvine CA). Quantification of mRNA levels was done by QRT-PCR by real-time fluorescent using a Stratagene MX3000p as described previously [19], [20]. The data was normalized by Δ2Ct method using β-actin and the fidelity of the reactions were verified by melting point analysis. Data presented are the mean±SEM with respect to sedentary control values.

Statistical Analysis

Statistical analyses were performed using NCSS Software (NCSS, Kaysville UT). Where appropriate, student t-test or ANOVA was utilized, post-hoc analysis was done using a Fisher's LSD analysis. Values presented are mean±SEM and statistical significance was set at p<.05.

Results

At 9 months of age the GK weighed significantly less than the Wistar group (Table 1). When this difference was considered there was no indication of cardiac hypertrophy, but a significant increase in the Kidney/BW ratio was observed. Similar to previous reports the GK rats are both hyperglycemic and have impaired glucose tolerance (Figure 1).

Table 1
Morphometric Data.

An impaired vasodilator response has been observed in several models of diabetes. In the present study we observed that acetylcholine induced vasorelaxation was impaired in the small arteries of the diabetic GK (Figure 2A), while, no differences between control Wistar and diabetic GK were observed in response to SNAP(a NO donor) (Figure 2B). These results suggest that diabetes impaired NO bioavailability. One underlying mechanism for impaired NO bioavailability is superoxide reaction to convert NO to ONOO and H2O. TO determine if superoxide was increased in the diabetic artery, tissue was stained using DHE. As shown in Figure 3, we observed significant increases in the present of superoxide.

Figure 2
Vasorelaxation of small arteries (<150 µm) from 9 month-old GK or Wistar rats is endothelia dependent.
Figure 3
DHE fluorescence staining for superoxide.

Similar to our earlier findings in the myocardium [7], NADPH directed lucigenin chemiluminescence was significantly increased in the diabetic aorta compared to the Wistar controls (Figure 4). No differences in NADH directed lucigenin chemiluminescence were observed (data not shown). The presence NAD(P)H inhibitors including pg91ds-tat, apocynin, and diphenyleneiodonium all reduced chemiluminescence and no differences between the Wistar and GK groups were observed (Figure 4).

Figure 4
Diabetes significantly increased superoxide production in aortic tissue.

Superoxide may be derived from several sources including mitochondria, monomeric eNOS, and NAD(P)H oxidase. We have previously observed that apocynin (an NAD(P)H oxidase inhibitor) decrease NAD(P)H-directed superoxide generation in the myocardium [21]. To determine the potential role of NAD(P)H derived superoxide on vascular function, the aorta was preincubated in apocynin. In response to acetylcholine induced vasorelaxation, no differences in vasorelaxation between diabetic and control aortas were observed (Figure 5). This would suggest that NAD(P)H derived superoxide generation may have been the underlying cause of vasoactive dysfunction in GK arteries.

Figure 5
Apocynin restores vasorelaxation of the diabetic aorta.

NAD(P)H oxidase consisting of 6 subunits and regulation of its activity is a complex event that we only now just beginning to understand. One possibility is an increase in the presence of the responsible components. Etoh et al. reported that the expression of both Nox4 and p22phox were increased in a STZ-induced model of diabetes [8]. To that end we have examined expression of NAD(P)H oxidase components at both the protein and mRNA levels. We found no significant differences in expression between the Wistar and GK aortas (Figure 6).

Figure 6
Diabetes did not significantly alter NOX protein expression.

Discussion

The GK rats are a nonobese model of NIDDM that have elevated fasting glucose, impaired response to glucose, and increased HbA1c levels at an early age [9], [10], [11]. Compared to other animal models of diabetes, the GK rats are not hyperlipidemic or hypercholesterolemic and present as a model of hyperglycemia. We have previously determined that GK hyperglycemia is progressive with age and that exercise training will significantly lower fasting blood glucose (sedentary; 205±9, exercise trained; 174±9 mg%) [20]. Although not hypertensive, the GK rats exhibit a small but significant increase MAP and systolic blood pressure compared to their Wistar controls [22]. GK rats present with many diabetic related complications observed in human diabetic patients, including reduced nerve conduction velocity and progressive renal involvement with thickening of the glomerular basement membranes [10], [13], [23], [24], [25], [26], [27]. It has been suggested that impaired pancreatic mitochondrial function may partially explain the depressed insulin release [28], [29]. Whether this is related to a shift in mitochondrial antioxidative capacity resulting in accelerated apoptosis is unclear [30]. Beta-cell mass and beta-cell replication is decreased in the GK pancreas and as such the GK rat may represent a model of beta-cell degradation for human NIDDM [31], [32], [33]. Genetic linkage analysis of the Goto-Kakizaki rats has localized different quantitative trait loci to those involved in diabetes [33], [34], [35], [36], [37]. Some regions show remarkable synteny homology to the diabetic loci found within human chromosome 1q21–25 [34], [35]. More recently Rosengren et. al. identified a polymorphism in the GK that resulted overexpression of the α2A-adrenergic receptor leading to depressed insulin sensitivity [37]. This polymorphism was also associated with a decreased insulin sensitivity in humans supporting the concept decreased insulin sensitivity may be one contributing cause of NIDDM, further linking the GK model to the human condition.

Diabetes impacts the vasculature on several levels. Increased generation of reactive oxygen species leading to endothelial dysfunction is believed to be the major cause of vascular dysfunction and coronary artery disease in diabetes. The GK rats represent a model to examine the role of hyperglycemic in diabetes. The major findings from this study are that chronic hyperglycemia induces significant vascular dysfunction in both the aorta and small arteries. Our studies indicate that NAD(P)H oxidase accounts for a significant portion of intracellular ROS in the vasculature. Hyperglycemic induced increases in NAD(P)H oxidase activity did not come from an increase in the expression of the NAD(P)H oxidase subunits, but more likely as a result of chronic activation via intracellular signaling pathways.

Endothelium-dependent macrovascular dysfunction has been observed in several models of diabetes and our results are similar to others for the larger conduit vessels [22], [38], [39]. Decreased endothelial-dependent relaxation of GK aorta and small skeletal muscle arteries (Figs. 2 & 5), suggest that endothelium-derived NO is inactivated presumably by hyperglycemia-induced oxidative stress. Although not hypertensive, the GK rats have a small but significant increase in MAP and systolic blood pressure compared to their Wistar controls, and have found to be salt sensitive [22]. Our findings are consistent with an increase in blood pressure as a function of vascular pathology.

NAD(P)H oxidase, the mitochondrial electron transport chain, and dysfunctional nitric oxide synthase are the three major sources of ROS within the cell. Although these sources are thought of as separate entities, recent papers have suggested significant interactions [40], [41], [42], [43], [44]. Any source of superoxide will exacerbate the conversion of NO to ONOO and uncoupled eNOS and increased iNOS expression have both been shown to contribute to oxidant stress in diabetes [40], [41], [45]. In obese models of NIDDM, NAD(P)H oxidase derived ROS is increased, and it has been suggested that elevated vasculature ROS contributes to mitochondrial dysfunction in the GK rat [7], [46], [47]. NOX4 is constitutively active not requiring activation by p47phox or p67phox and its expression is increased in diabetes and aging [42], [44]. Subcellular localization of NOX4 is cell type dependent with NOX4 being localized to the mitochondria in cardiomyocytes, in the nucleus of endothelial cells, and at focal adhesions within vascular smooth muscle [42], [43], [44], [48], [49]. Within vascular smooth muscle, NOX4 is involved in maintenance of the smooth muscle phenotype and localization to focal adhesions suggests its participation in cell migration [49], [50]. Localization of NOX4 to the endothelial nuclei could significantly accelerate oxidant stress induce DNA modifications [49]. In the present study, we find, using an animal model of chronic hyperglycemia, significant increases ROS generation via elevated NAD(P)H oxidase activity. The NAP(P)H inhibitors apocynin as well as gp91ds-tat, and DPI all reduced superoxide generation by NAD(P)H oxidase in aortic extracts. Blockage of NAD(P)H oxidase by apocynin restored endothelial dependent vasorelaxation. Although our present results clearly demonstrated NADPH oxidase impacts on endothelial dependent vasculature function, future work to more clearly examine diabetic induced changes in NADPH oxidase by cell type and subcellular local are warranted.

Chronic hyperglycemia did not increased expression of several components of the NAD(P)H oxidase system and this was observed at both the protein and mRNA levels These results are similar to the Zucker fa/fa/rat (type 2) but differ from that observed by Bitnar et.al who observed increases in p47phox in younger GK rats [8], [51], [52]. Other studies examining T1D models observed significant increases in NAD(P)H oxidase subunit expression in the heart and the vasculature suggesting that the pathogenic mechanisms are not necessarily similar in all models of diabetes [41], [53] In the vasculature, the increase was evident after 4 weeks but not 16 weeks of diabetes suggesting that altered NAD(P)H oxidase expression may be a transitional event [53]. The increased NAD(P)H oxidase activity observed in the present study may have arisen as a function of chronic activation of the oxidase, either by increased substrate presentation or increased turnover. Kitahara et.al reported that G6PD activity is significantly elevated in GK rat liver and we have observed similar increases in the myocardium from the Zucker fa/fa rat [51], [54]. The primary function of G6PD is to produce NADPH within the cells and its chronic activation will elevate NAD(P)H levels. In the Zucker fa/fa rat, chronic activation of glucose-6-phosphate dehydrogenase (G6PD) was brought about via a Src kinase [51]. More recently, Liu reported that high glucose will increased p47phox phosphorylation leading to activation of NAD(P)H oxidase [55]. Others have reported that high glucose will enhance p47phox translocation into the membrane promoting activation of NAD(P)H oxidase [56]. Collectively these reports suggest that NAD(P)H oxidase activity may be the result of increased activation.

The GK rats are a model of type II diabetes that presents with hyperglycemia but without severe hyperlipidemia. We have found that endothelial-dependent dysfunction was observed in both large and small arteries. Endothelial dysfunction was brought about as a result of increased intracellular superoxide generation that was likely to be the result of chronic activation of NAD(P)H oxidase activity.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: Supported by the National Institutes of Health under the following grant numbers: HL077256, HL43023, HL085352; as well by the American Heart Association (Grant#0435070). These funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004;25:543–567. [PubMed]
2. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res. 2006;98:596–605. [PubMed]
3. Bath PM, Hassall DG, Gladwin AM, Palmer RM, Martin JF. Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler Thromb. 1991;11:254–260. [PubMed]
4. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:1774–1777. [PMC free article] [PubMed]
5. Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987;92:639–646. [PMC free article] [PubMed]
6. Meininger CJ, Marinos RS, Hatakeyama K, Martinez-Zaguilan R, Rojas JD, et al. Impaired nitric oxide production in coronary endothelial cells of the spontaneously diabetic BB rat is due to tetrahydrobiopterin deficiency. Biochem J. 2000;349:353–356. [PubMed]
7. Serpillon S, Floyd BC, Gupte RS, George S, Kozicky M, et al. Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH. Am J Physiol Heart Circ Physiol. 2009;297:H153–162. [PubMed]
8. Etoh T, Inoguchi T, Kakimoto M, Sonoda N, Kobayashi K, et al. Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabetologia. 2003;46:1428–1437. [PubMed]
9. Yasuda K, Nishikawa W, Iwanaka N, Nakamura E, Seino Y, et al. Abnormality in fibre type distribution of soleus and plantaris muscles in non-obese diabetic Goto-Kakizaki rats. Clin Exp Pharmacol Physiol. 2002;29:1001–1008. [PubMed]
10. Yagihashi S, Goto Y, Kakizaki M, Kaseda N. Thickening of glomerular basement membrane in spontaneously diabetic rats. Diabetologia. 1978;15:309–312. [PubMed]
11. Goto Y, Kakizaki M, Masaki N. Production of a spontaneous diabetic rats by repetition of selective breeding. Tohoku J Exp Med. 1976;119:85–90. [PubMed]
12. Debin R, Lauzier B, Sicard P, Delemasure S, Amoureux S, et al. Are Zucker obese rats a useful model for cardiovascular complications in metabolic syndrome? Physical, biochemical and oxidative stress considerations. Fundam Clin Pharmacol. 2009;23:59–67. [PubMed]
13. Vesely DL, Gower WR, Jr, Dietz JR, Overton RM, Clark LC, et al. Elevated atrial natriuretic peptides and early renal failure in type 2 diabetic Goto-Kakizaki rats. Metabolism. 1999;48:771–778. [PubMed]
14. Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008;8:157–168. [PMC free article] [PubMed]
15. Csiszar A, Labinskyy N, Perez V, Recchia FA, Podlutsky A, et al. Endothelial function and vascular oxidative stress in long-lived GH/IGF-deficient Ames dwarf mice. Am J Physiol Heart Circ Physiol. 2008;295:H1882–1894. [PubMed]
16. Ungvari Z, Pacher P, Kecskemeti V, Papp G, Szollar L, et al. Increased myogenic tone in skeletal muscle arterioles of diabetic rats. Possible role of increased activity of smooth muscle Ca2+ channels and protein kinase C. Cardiovasc Res. 1999;43:1018–1028. [PubMed]
17. Csiszar A, Labinskyy N, Smith K, Rivera A, Orosz Z, et al. Vasculoprotective effects of anti-tumor necrosis factor-alpha treatment in aging. Am J Pathol. 2007;170:388–398. [PubMed]
18. Ungvari Z, Csiszar A, Edwards JG, Kaminski PM, Wolin MS, et al. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol. 2003;23:418–424. [PubMed]
19. Rafalski K, Abdourahman A, Edwards JG. Early adaptations to training: upregulation of alpha-myosin heavy chain gene expression. Med Sci Sports Exerc. 2007;39:75–82. [PubMed]
20. Hainsey T, Csiszar A, Sun S, Edwards JG. Cyclosporin A does not block exercise-induced cardiac hypertrophy. Med Sci Sports Exerc. 2002;34:1249–1254. [PubMed]
21. Grijalva J, Hicks S, Zhao X, Medikayala S, Kaminski PM, et al. Exercise training enhanced myocardial endothelial nitric oxide synthase (eNOS) function in diabetic Goto-Kakizaki (GK) rats. Cardiovasc Diabetol. 2008;7:34. [PMC free article] [PubMed]
22. Cheng ZJ, Vaskonen T, Tikkanen I, Nurminen K, Ruskoaho H, et al. Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension. 2001;37:433–439. [PubMed]
23. Janssen U, Riley SG, Vassiliadou A, Floege J, Phillips AO. Hypertension superimposed on type II diabetes in Goto Kakizaki rats induces progressive nephropathy. Kidney Int. 2003;63:2162–2170. [PubMed]
24. Phillips AO, Baboolal K, Riley S, Grone H, Janssen U, et al. Association of prolonged hyperglycemia with glomerular hypertrophy and renal basement membrane thickening in the Goto Kakizaki model of non-insulin-dependent diabetes mellitus. Am J Kidney Dis. 2001;37:400–410. [PubMed]
25. Yagihashi S, Kaseda N, Kakizaki M, Goto Y. Evolution of glomerular lesions in rats with spontaneous diabetes. Tohoku J Exp Med. 1979;127:359–367. [PubMed]
26. Yagihashi S, Tonosaki A, Yamada K, Kakizaki M, Goto Y. Peripheral neuropathy in selectively-inbred spontaneously diabetic rats: electrophysiological, morphometrical and freeze-replica studies. Tohoku J Exp Med. 1982;138:39–48. [PubMed]
27. Murakawa Y, Zhang W, Pierson CR, Brismar T, Ostenson CG, et al. Impaired glucose tolerance and insulinopenia in the GK-rat causes peripheral neuropathy. Diabetes Metab Res Rev. 2002;18:473–483. [PubMed]
28. Oliveira PJ, Rolo AP, Seica R, Sardao V, Monteiro P, et al. Impact of diabetes on induction of the mitochondrial permeability transition. Rev Port Cardiol. 2002;21:759–766. [PubMed]
29. Oliveira PJ, Rolo AP, Seica R, Palmeira CM, Santos MS, et al. Decreased susceptibility of heart mitochondria from diabetic GK rats to mitochondrial permeability transition induced by calcium phosphate. Biosci Rep. 2001;21:45–53. [PubMed]
30. Ferreira FM, Palmeira CM, Matos MJ, Seica R, Santos MS. Decreased susceptibility to lipid peroxidation of Goto-Kakizaki rats: relationship to mitochondrial antioxidant capacity. Life Sci. 1999;65:1013–1025. [PubMed]
31. Movassat J, Saulnier C, Serradas P, Portha B. Impaired development of pancreatic beta-cell mass is a primary event during the progression to diabetes in the GK rat. Diabetologia. 1997;40:916–925. [PubMed]
32. Portha B, Giroix MH, Serradas P, Gangnerau MN, Movassat J, et al. beta-cell function and viability in the spontaneously diabetic GK rat: information from the GK/Par colony. Diabetes. 2001;50(Suppl 1):S89–93. [PubMed]
33. Portha B, Lacraz G, Kergoat M, Homo-Delarche F, Giroix MH, et al. The GK rat beta-cell: a prototype for the diseased human beta-cell in type 2 diabetes? Mol Cell Endocrinol. 2009;297:73–85. [PubMed]
34. Wallis RH, Collins SC, Kaisaki PJ, Argoud K, Wilder SP, et al. Pathophysiological, genetic and gene expression features of a novel rodent model of the cardio-metabolic syndrome. PLoS One. 2008;3:e2962. [PMC free article] [PubMed]
35. Wallace KJ, Wallis RH, Collins SC, Argoud K, Kaisaki PJ, et al. Quantitative trait locus dissection in congenic strains of the Goto-Kakizaki rat identifies a region conserved with diabetes loci in human chromosome 1q. Physiol Genomics. 2004;19:1–10. [PubMed]
36. Lin JM, Ortsater H, Fakhrai-Rad H, Galli J, Luthman H, et al. Phenotyping of individual pancreatic islets locates genetic defects in stimulus secretion coupling to Niddm1i within the major diabetes locus in GK rats. Diabetes. 2001;50:2737–2743. [PubMed]
37. Rosengren AH, Jokubka R, Tojjar D, Granhall C, Hansson O, et al. Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes. Science. 2010;327:217–220. [PubMed]
38. Kobayashi T, Matsumoto T, Ooishi K, Kamata K. Differential expression of alpha2D-adrenoceptor and eNOS in aortas from early and later stages of diabetes in Goto-Kakizaki rats. Am J Physiol Heart Circ Physiol. 2004;287:H135–148. [PubMed]
39. Witte K, Jacke K, Stahrenberg R, Arlt G, Reitenbach I, et al. Dysfunction of soluble guanylyl cyclase in aorta and kidney of Goto-Kakizaki rats: influence of age and diabetic state. Nitric Oxide. 2002;6:85–95. [PubMed]
40. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, et al. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol. 2007;293:H610–619. [PMC free article] [PubMed]
41. Rajesh M, Mukhopadhyay P, Batkai S, Mukhopadhyay B, Patel V, et al. Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy. J Cell Mol Med. 2009;13:2330–2341. [PMC free article] [PubMed]
42. Block K, Gorin Y, Abboud HE. Subcellular localization of Nox4 and regulation in diabetes. Proc Natl Acad Sci U S A. 2009;106:14385–14390. [PubMed]
43. Graham KA, Kulawiec M, Owens KM, Li X, Desouki MM, et al. NADPH oxidase 4 is an oncoprotein localized to mitochondria. Cancer Biol Ther. 10 [PMC free article] [PubMed]
44. Ago T, Kuroda J, Pain J, Fu C, Li H, et al. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res. 2010;106:1253–1264. [PMC free article] [PubMed]
45. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest. 2002;109:817–826. [PMC free article] [PubMed]
46. Sonta T, Inoguchi T, Tsubouchi H, Sekiguchi N, Kobayashi K, et al. Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity. Free Radic Biol Med. 2004;37:115–123. [PubMed]
47. Rosen P, Wiernsperger NF. Metformin delays the manifestation of diabetes and vascular dysfunction in Goto-Kakizaki rats by reduction of mitochondrial oxidative stress. Diabetes Metab Res Rev. 2006;22:323–330. [PubMed]
48. Kuroda J, Nakagawa K, Yamasaki T, Nakamura K, Takeya R, et al. The superoxide-producing NAD(P)H oxidase Nox4 in the nucleus of human vascular endothelial cells. Genes Cells. 2005;10:1139–1151. [PubMed]
49. Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, Griendling KK. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2004;24:677–683. [PubMed]
50. Clempus RE, Sorescu D, Dikalova AE, Pounkova L, Jo P, et al. Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol. 2007;27:42–48. [PMC free article] [PubMed]
51. Gupte RS, Floyd BC, Kozicky M, George S, Ungvari ZI, et al. Synergistic activation of glucose-6-phosphate dehydrogenase and NAD(P)H oxidase by Src kinase elevates superoxide in type 2 diabetic, Zucker fa/fa, rat liver. Free Radic Biol Med. 2009;47:219–228. [PMC free article] [PubMed]
52. Bitar MS, Wahid S, Mustafa S, Al-Saleh E, Dhaunsi GS, et al. Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes. Eur J Pharmacol. 2005;511:53–64. [PubMed]
53. Ding H, Hashem M, Triggle C. Increased oxidative stress in the streptozotocin-induced diabetic apoE-deficient mouse: changes in expression of NADPH oxidase subunits and eNOS. Eur J Pharmacol. 2007;561:121–128. [PubMed]
54. Kitahara A, Toyota T, Kakizaki M, Goto Y. Activities of hepatic enzymes in spontaneous diabetes rats produced by selective breeding of normal Wistar rats. Tohoku J Exp Med. 1978;126:7–11. [PubMed]
55. Liu S, Ma X, Gong M, Shi L, Lincoln T, et al. Glucose down-regulation of cGMP-dependent protein kinase I expression in vascular smooth muscle cells involves NAD(P)H oxidase-derived reactive oxygen species. Free Radic Biol Med. 2007;42:852–863. [PubMed]
56. Kinoshita H, Matsuda N, Kaba H, Hatakeyama N, Azma T, et al. Roles of phosphatidylinositol 3-kinase-Akt and NADPH oxidase in adenosine 5′-triphosphate-sensitive K+ channel function impaired by high glucose in the human artery. Hypertension. 2008;52:507–513. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science